CTORCitius Oncology Inc. Common Stock
0.7438USD-1.16%Mkt Cap: 78.66M $P/E: —3d ago
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed…
Industry Peers
Drug Manufacturers - Specialty & Generic$65.19BUSDP/E 23.7
$58.06BUSD
$43.98BUSDP/E 20.4
$43.51BUSDP/E 62.2
$29.89BUSDP/E 12.7
$32.12BUSDP/E 12.7
$22.01BUSDP/E 18.4
$18.75BUSD
$15.34BUSDP/E 117.3
$14.67BUSDP/E 26.4
$15.51BUSDP/E 22.3
$11.98BUSD
$10.15BUSDP/E 29.7
$8.66BUSDP/E 19.0
$8.11BUSDP/E 127.2
$7.88BUSD
$6.53BUSDP/E 23.9
$6.24BUSDP/E 37.3
$6.14BUSDP/E 49.0
$6.08BUSDP/E 79.8
| Headline | Source | Time |
|---|---|---|
Older | ||
 Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10. | ||